A total of 65 adults with acute lymphoblastic leukemia (ALL) received 200 mg/m 2 melphalan and an autograft in first remission, with a plan to receive 6-mercaptopurine (6MP), methotrexate (MTX), and vincristine-prednisone (VP) for 2 years afterwards. There was no transplantrelated mortality. In all, 69% of patients received 6MP, 54% received MTX, and 49% received VP. The cumulative incidence of relapse at 5 years was 52%.
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We have attempted to improve 1 the relatively poor results of high-dose therapy and autotransplantation in adult acute lymphoblastic leukemia (ALL) [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] by administering maintenance chemotherapy with 6-mercaptopurine (6MP), methotrexate (MTX) and vincristine-prednisone (VP) for 2 years after transplantation. The results, using melphalan with total-body irradiation (TBI) and autologous bone marrow initially and high-dose melphalan alone with blood-derived stem cells subsequently, have been very encouraging and strongly suggest that post transplant maintenance chemotherapy is useful. 1 Our previous report on the outcome of this strategy included patients conditioned with melphalan-TBI as well as melphalan, and some patients who had received purged marrow. 1 The current report includes a homogeneously treated group of 65 patients conditioned with high-dose melphalan (200 mg/m 2 ) and receiving unpurged bloodderived stem cells; 42 of whom were included in the previous report. The report provides longer follow-up (just over 10 years) and assesses applicability of this TBI-free treatment modality in older patients. Also, a significantly larger proportion of patients in this group were treated with a more intensive remission-induction and intensification regimen; allowing assessment of the contribution of the intensity of the pre-transplant conventional therapy to outcome.
Patients and methods
All data were gathered prospectively. 16 All consecutive patients over the age of 15 years who were autografted for ALL in first CR between January 1993 and February 2003 at the Leukaemia Unit of the Royal Marsden Hospital were included. Table 1 shows the patient characteristics.
Autotransplantation was performed as the procedure of choice irrespective of the availability of matched sibling donors as part of our 'sequential high-dose therapy' approach; the idea being to perform a low-morbidity autograft as the first step -followed by a salvage allograft in second remission in relapsing patients. Exceptions to the sequential high-dose therapy approach included patients taking 48 weeks to attain CR, those with CNS disease and t(9;22) -who were allografted in first CR if an HLAmatched sibling donor was available. Patients with t(9;22) were preferentially transplanted from unrelated donors in the absence of a suitable sibling donor -which explains the low number of patients with Ph þ disease in this series.
Patients with lymphoid blast crisis of chronic myeloid leukemia were not included. Patients with biphenotypic disease (presence of myeloid markers) and those with Burkitt-type disease (FAB type L3) received different initial chemotherapy and were excluded. The transplants were performed as part of the standard therapy of adult ALL, and were not performed on a clinical protocol evaluating the utility of transplantation. All research protocols were approved by the local institutional review board. All patients gave informed consent for transplantation. 
Induction chemotherapy

Central nervous system prophylaxis
Patients received 2400 cGy cranial irradiation in 15 fractions after hematologic recovery from intensification or phase II induction and before leukapheresis. No patient received testicular irradiation. Patients without CNS disease received six injections of intrathecal MTX (usually 15 mg) over the treatment period prior to the transplant, and the two with CNS disease received triple intrathecal chemotherapy with MTX (15 mg), cytarabine (30 mg), and hydrocortisone (100 mg) until six consecutive spinal fluid samples were free of disease. No intrathecal chemotherapy was administered post transplant based upon our observation that isolated CNS recurrence is exceedingly rare after transplantation in first remission acute leukemia. 17 
Peripheral blood stem cell harvest
The first seven patients received G-CSF (filgrastim) at the dose of 125 mg/m 2 subcutaneously q12 h starting 2 weeks after a back-up bone marrow harvest for a period of 7 days. Stem cells were harvested on days 5-8 (4 consecutive days). The next 58 patients received 12-16 mg/kg filgrastim subcutaneously q24 h on days 1-4, and stem cells were harvested on days 4 and 5. Leukapheresis was performed on a Cobe Spectra (Cobe Industries, Lakewood, CO, USA) continuous-flow cell separator with 150-200% of the patient's calculated blood volume being processed at each session.
Cryopreservation and infusion
Cells were cryopreserved with 10% dimethylsulfoxide using a controlled-rate freezer and were stored in the vapor phase of liquid nitrogen. The cells were rapidly thawed in a water bath at 371C by the bedside and infused within 2 weeks of collection.
High-dose therapy and transplant
The conditioning regimen comprised a single dose of 200 mg/m 2 melphalan with hydration on day À1. All cryopreserved cells (excluding back-up marrow) were infused on day 0; 24 h after the administration of melphalan. No growth factors were administered post transplant to accelerate myeloid recovery. a Six patients had Ph+ disease detected on conventional cytogenetic studies (G-banding). RT-PCR was not performed routinely. It is therefore possible that the actual proportion of patients with Ph+ disease may be higher.
Supportive care
All patients were treated in protective isolation in rooms with positive-pressure ventilation. Blood products transfused were not screened for cytomegalovirus (CMV) antibody in CMV-seropositive patients. Antibiotic prophylaxis and therapy varied in accordance with prevalent practices and research programs. Broad-spectrum antibiotic therapy was started for fever in the neutropenic phase. Irradiated random platelets were transfused to maintain the platelet count at 20 Â 10 9 /l, and packed cells to maintain the hemoglobin at 100 g/l.
Maintenance chemotherapy
Maintenance chemotherapy with daily 6MP was usually begun when the leukocytes reached 3 Â 10 9 /l and the platelets 100 Â 10 9 /l, and was continued for 2 years. Commencement of chemotherapy was not delayed by any factor except for poor hematologic recovery, relapse or ongoing medical problems (eg interstital pneumonitis), which could potentially be exacerbated by starting chemotherapy. Therapy was started with 25 mg 6MP and this was increased weekly or fortnightly in 25-50 mg steps. Weekly oral MTX at the dose of 5 mg (increasing in 2.5-5 mg steps) was added when the dose of 6MP reached 75 mg. All maintenance chemotherapy was discontinued 2 years after starting the first agent (6MP).
Drug doses were adjusted to maintain the absolute neutrophil count over 1 Â 10 9 /l. Initially, monthly vincristine (1.4 mg/m 2 ; maximum 2 mg) with prednisone (40 mg/ m 2 for a week) were administered to patients who could not tolerate myelosuppressive chemotherapy. After 1995, this was added routinely to all patients.
The target doses of 6MP and MTX were 80 mg/m 2 daily and 20 mg/m 2 weekly, respectively. Patients received folic acid and prophylaxis for Pneumocystis carinii pneumonia with oral trimethoprim-sulfamethoxazole (if on 50% of the target 6MP dose) or aerosolized pentamidine (if on less than 50% of target 6MP dose) while on maintenance chemotherapy. Acyclovir was administered to prevent reactivation of Varicella zoster virus.
Statistical analysis
The probabilities of disease-free survival (DFS) and overall survival (OS) were estimated by the Kaplan-Meier method, and compared using the log-rank test. The cumulative incidence of relapse was estimated using other events (only one in this series; a homicide) as competing risks. The significance of differences in relapse was calculated using the likelihood-ratio statistic for proportional-hazards regression models.
One patient died in CR from homicide 8 months post transplant, and was censored at the time of death for OS and DFS, and was considered to have had a competing event for calculating the cumulative incidence of relapse. One patient was lost to follow-up after having relapsed less than 3 months after the transplant. This patient was considered to have died at the date of the last follow-up for estimating OS.
The disease risk stratification was based upon age, cytogenetics, and the time taken to attain CR (Table 2) , and was a modification of the German classification proposed by Hoelzer et al. 18 The following factors were analyzed in Cox proportional-hazards regression models for effect on relapse, DFS, and OS: disease risk (standard vs intermediate vs high), gender, CR-transplant interval (o4 vs X4 months), type of induction therapy (UKALL X or similar vs UKALL XII or similar), WBC count at presentation (o30 vs X30 Â 10 9 /l), intensity of maintenance therapy (0/1 agent vs 2/3 agents, and 0 vs 1 vs 2 vs 3 agents), and immunophenotype (null vs others).
Patient follow-up data are current through 5 August 2003 when the median, minimum, and maximum follow-up duration for surviving patients was 5.0, 0.5, and 10.5 years, respectively.
Results
Neutrophil recovery to 0.5 Â 10 9 /l was complete and sustained in all patients. No patient died of treatmentrelated causes. Table 3 shows the time to starting each maintenance chemotherapy agent and the proportion of patients starting it. None of the 20 patients who did not receive 6MP received MTX, whereas eight received VP.
Maintenance chemotherapy
A total of 12 patients received no maintenance chemotherapy at all because of relapse within 4 months (n ¼ 2), sluggish hematologic recovery terminating in relapse beyond 4 months (n ¼ 3), unknown/patient preference (n ¼ 6), and noncompliance/lifestyle (n ¼ 1; this patient eventually became a homicide victim). A total of 11 patients received only 1 drug (eight VP and three 6MP), 25 received two drugs (18 6MP-MTX and 7 6MP-VP), and 17 received all the three drugs.
Maintenance chemotherapy was tolerated well, and other than transient myelosuppression requiring dose reduction or temporary cessation of therapy, no other side effects were seen.
Relapse and post-relapse therapy
A total of 30 patients (39%) relapsed at 2-49 months (median 9); 18 in the first year, seven in the second year, four in the fourth, and one in the fifth. Figure 1 shows the cumulative incidence of relapse. Relapsed disease was confirmed to be identical to the original disease in all cases, and no case of second or secondary leukemia was seen. Not a single relapse was an isolated extramedullary event.
In all, 16 patients died of relapsed disease or toxicity of salvage chemotherapy; 12 underwent allografts from an HLA-matched sibling (n ¼ 6) or unrelated (n ¼ 6) donor in second CR, and two are alive in second CR (one awaiting an allograft, and one who refused an allograft and is 15 months into the second CR). The conditioning regimen for the allografts was 60 mg/kg etoposide and 1050 cGy singlefraction TBI, the marrow or blood stem cells were unmanipulated and graft-versus-host disease prophylaxis comprised cyclosporine and methotrexate. A total of 11 died of transplant-related toxicity (n ¼ 7) or relapse (n ¼ 4), and one is alive and well in second CR 9 years after an allograft from an HLA-identical sibling.
Overall and disease-free survival
As of 5 August 2003, 38 patients were alive and in remission 6 months to 10.5 years (median 5 years) after the transplant; 35 in continuous first CR. Figure 2 shows the actuarial probabilities of DFS and OS.
Identification of risk groups
The three adverse risk factors; age 430 years, t(9;22), t(4;11), and 44 weeks to attain CR; affected relapse, DFS and OS, significantly (Table 2) . These factors could be combined to produce three risk groups (no adverse factor, one adverse factor, or 2-3 adverse factors). The relapse rates and DFS of these three groups were significantly different ( Figures 3 and 4) .
The effect of maintenance chemotherapy
Among the 62 patients alive and well at 120 days, increasing intensity of maintenance chemotherapy was associated with a significantly lower relapse rate ( Figure 5 ) and higher DFS ( Figure 6 ). This time point was chosen to eliminate patients relapsing early; before becoming eligible to receive maintenance chemotherapy. Table 4 shows the results of the multivariable analysis adjusted by survival on day 120 post transplant. Standardrisk disease, more intense maintenance chemotherapy, and lower leukocyte count at presentation were associated with higher DFS and OS. Since there were no treatment-related deaths, the analysis for factors affecting relapse yielded results that were identical to DFS. Expectedly, a longer CR-transplant interval was associated with better outcome, although the difference was only of borderline significance (P ¼ 0.09).
Cox analysis
The effect of maintenance chemotherapy by risk group Table 5 shows that receiving more intensive maintenance chemotherapy made a significant difference to outcome in the standard-risk group and a less-marked difference to patients in the intermediate-risk group. On the other hand, it made no difference to patients in the high-risk group at all.
Discussion
These data confirm our previous findings that maintenance chemotherapy can be administered safely after autotransplantation to patients with ALL. 1 Despite the overlap in patients between the previous series 1 and this one, there are important differences between the two reports that provide new insights into the utility of autotransplantation followed by maintenance chemotherapy.
In the previous series, difference in outcome was based upon 0-1 vs 2-3 maintenance chemotherapy agents. Here, there is a much clearer trend illustrating the benefit of each additional maintenance chemotherapy agent (Figures 5 and  6 ). We believe that short of a prospective randomized study, this is the strongest evidence that can be obtained to support the use of maintenance chemotherapy after autotransplantation in ALL. Owing to the retrospective nature of the observations, it should be emphasized that the ability to start and tolerate maintenance chemotherapy may have been a marker for a better overall situation; with the better outcome being attributable more to the clinical situation than to maintenance chemotherapy.
There were some treatment-related deaths in the previous secondary to the use of TBI. The use of a radiation-free regimen has eliminated TRM completely. It is unclear if the antileukemic efficacy of the procedure has been compromised by this, although our previous experience suggests that it has not. 1 The interesting implication of the elimination of TBI is that it could make the procedure more easily applicable to much younger patients (no Figure 6 The effect of maintenance chemotherapy on disease-free survival in 62 patients alive and well on day 120 following the autograft (P ¼ 0.0097).
long-term consequences of TBI) as well as to significantly older patients (no acute toxicity from TBI).
The UKALL XII regimen is considerably more complex and intense than the UKALL X regimen in the induction as well as the early intensification and consolidation phases. It was therefore disappointing to see that it did not affect the outcome beneficially. This is in contrast to our observations in acute myeloid leukemia where the overall intensity of prior therapy (specifically consolidation) does affect outcome after autograft significantly; 19 with more intense prior therapy being associated with lower post transplant relapse and better DFS. One possibly critical and wide-ranging implication of this observation is that a safe autograft procedure following standard four-drug induction and modest intensification/consolidation followed by simple maintenance chemotherapy could potentially replace very complex ALL treatment regimens, which have failed in developing countries due to practical difficulties in implementing them. 20 is powerful in predicting outcome. Autotransplantation is totally inadequate for high-risk patients who must be allografted -using alternative donors if necessary. On the other hand, the nontoxic approach is very successful in patients with lowrisk disease. Such patients, in our opinion, should not be allografted in first CR even if they have an HLA-identical sibling donor because of the excellent results seen with autotransplantation.
However, patients with a reasonably high chance of relapse -such as those in the intermediate-risk groupought to be allografted if there is an HLA-matched sibling 23 Greater refinement of prognostic factors would be helpful -with patients with higher risk disease being subjected to allogeneic transplantation and those with lower risk disease being autografted. The excellent tolerance of melphalan at the dose of 200 mg/m 2 suggests that there could be a place for dose escalation in intermediate-risk group patients subjected to autotransplantation in the form of a higher dose of melphalan (possibly with amifostine), or addition of etoposide, a monoclonal antibody such as rituximab or alemtuzumab (depending upon the characteristics of the specific patient being treated), a radiolabeled monoclonal antibody, or skeletal-targeted radiation with bone-seeking radioconjugated chelates.
Patients relapsing after an autograft are unlikely to benefit from a conventional etoposide-TBI allograft as performed here, even with the superior graft-versusleukemia effects exerted by the use of blood-derived stem cells. 24 A submyeloablative conditioning regimen with GVHD prophylaxis adjusted towards high-risk disease may provide better results.
We conclude that 200 mg/m 2 autotransplantation followed by maintenance chemotherapy is an effective and safe way of intensifying therapy in adult patients with ALL. This strategy deserves consideration as consolidation therapy for all low-risk and a proportion of intermediaterisk adult patients (up to the age of 70 years) with ALL. Trials in pediatric ALL patients, particularly geared towards developing countries, may also be worthwhile. This approach should be systematically evaluated in a large cooperative study such as the one that will replace the ongoing joint UK ALL XII and Eastern Cooperative Oncology Group (ECOG) 2993 study.
